Amarin (AMRN) Competitors $14.92 +0.32 (+2.19%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$14.92 +0.01 (+0.03%) As of 09/18/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. TLRY, EVO, RCUS, NTLA, TRML, PHVS, XERS, GPCR, CVAC, and ZYMEShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Tilray Brands (TLRY), Evotec (EVO), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Tourmaline Bio (TRML), Pharvaris (PHVS), Xeris Biopharma (XERS), Structure Therapeutics (GPCR), CureVac (CVAC), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Tilray Brands Evotec Arcus Biosciences Intellia Therapeutics Tourmaline Bio Pharvaris Xeris Biopharma Structure Therapeutics CureVac Zymeworks Amarin (NASDAQ:AMRN) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has higher valuation and earnings, AMRN or TLRY? Amarin has higher revenue and earnings than Tilray Brands. Amarin is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.35-$82.18M-$3.67-4.07Tilray Brands$210.48M6.59-$2.19B-$2.31-0.55 Do analysts rate AMRN or TLRY? Amarin presently has a consensus price target of $12.00, suggesting a potential downside of 19.57%. Tilray Brands has a consensus price target of $1.94, suggesting a potential upside of 53.77%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts clearly believe Tilray Brands is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Tilray Brands 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is AMRN or TLRY more profitable? Amarin has a net margin of -47.22% compared to Tilray Brands' net margin of -265.69%. Tilray Brands' return on equity of -6.83% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-47.22% -21.18% -15.00% Tilray Brands -265.69%-6.83%-5.45% Does the media prefer AMRN or TLRY? In the previous week, Tilray Brands had 16 more articles in the media than Amarin. MarketBeat recorded 18 mentions for Tilray Brands and 2 mentions for Amarin. Tilray Brands' average media sentiment score of 0.96 beat Amarin's score of 0.93 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tilray Brands 12 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of AMRN or TLRY? 22.3% of Amarin shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 3.3% of Amarin shares are held by company insiders. Comparatively, 0.6% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, AMRN or TLRY? Amarin has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. SummaryTilray Brands beats Amarin on 11 of the 16 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$301.97M$3.12B$5.78B$10.28BDividend YieldN/A2.37%5.74%4.64%P/E Ratio-4.0721.3676.9426.98Price / Sales1.35475.60543.88128.54Price / CashN/A45.3237.1760.63Price / Book0.639.6913.836.37Net Income-$82.18M-$52.92M$3.29B$271.46M7 Day Performance-0.60%2.19%1.57%2.53%1 Month Performance-5.69%8.96%6.87%9.42%1 Year Performance24.62%10.84%81.59%30.16% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.5992 of 5 stars$14.92+2.2%$12.00-19.6%+25.0%$301.97M$228.61M-4.07360TLRYTilray Brands3.0522 of 5 stars$1.18+5.4%$1.94+64.2%-30.0%$1.23B$821.31M0.002,842EVOEvotec1.8913 of 5 stars$3.50+0.9%$5.40+54.3%+2.5%$1.23B$862.40M0.004,827Positive NewsGap UpRCUSArcus Biosciences2.0158 of 5 stars$11.57+0.4%$21.14+82.7%-24.3%$1.23B$258M-3.65500Positive NewsNTLAIntellia Therapeutics4.5054 of 5 stars$11.57+1.3%$27.11+134.3%-28.5%$1.23B$57.88M0.00600Options VolumeGap UpTRMLTourmaline Bio0.9335 of 5 stars$47.65+0.1%$45.65-4.2%+127.1%$1.22BN/A0.0044PHVSPharvaris2.4593 of 5 stars$23.38+0.8%$34.00+45.4%+21.1%$1.21BN/A0.0030Positive NewsXERSXeris Biopharma2.8539 of 5 stars$7.36-1.7%$7.08-3.8%+186.2%$1.21B$203.07M0.00290GPCRStructure Therapeutics3.5124 of 5 stars$20.20-3.4%$75.71+274.8%-39.3%$1.20BN/A0.00136Positive NewsGap UpCVACCureVac3.9341 of 5 stars$5.36+0.4%$6.83+27.5%+62.6%$1.20B$579.18M5.56880Short Interest ↑ZYMEZymeworks2.5704 of 5 stars$15.93+1.2%$21.43+34.5%+31.7%$1.20B$122.87M-10.62460Positive News Related Companies and Tools Related Companies Tilray Brands Alternatives Evotec Alternatives Arcus Biosciences Alternatives Intellia Therapeutics Alternatives Tourmaline Bio Alternatives Pharvaris Alternatives Xeris Biopharma Alternatives Structure Therapeutics Alternatives CureVac Alternatives Zymeworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.